Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.

导出 OA

翻译打印收藏纠错

作者： Sharon,McGee ^[1] ; Mashari,Alzahrani ^[2] ; Lisa,Vandermeer ^[1] ; Katherine,Cole ^[2] ; Gail,Larocque ^[1] ; Arif,Awan ^[3] ; Brian,Hutton ^[1] ; Gregory,Pond ^[2] ; Deanna,Saunders ^[4] ; Mark,Clemons ^[5]

作者单位： Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, 501 Smyth Road, Ottawa, Canada. ^[1] Cancer Therapeutics Program, Ottawa Hospital Research, and University of Ottawa, Ottawa, Canada. ^[2] The Ottawa Hospital Cancer Program, The Ottawa Hospital, Ottawa, Canada. ^[3] Clinical Epidemiology Program, The Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada. ^[4] Department of Oncology, Juravinski Cancer Centre and McMaster University, Hamilton, Canada. ^[5] Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, 501 Smyth Road, Ottawa, Canada. mclemons@toh.ca. ^[6] Cancer Therapeutics Program, Ottawa Hospital Research, and University of Ottawa, Ottawa, Canada. mclemons@toh.ca. ^[7]

关键词 Adjuvant bisphosphonates De-escalation Survey Zoledronate

主题词骨密度保护剂(Bone Density Conservation Agents);乳腺肿瘤(Breast Neoplasms);加拿大(Canada);二膦酸盐类(Diphosphonates);女(雌)性(Female);人类(Humans);肿瘤复发, 局部(Neoplasm Recurrence, Local)

DOI 10.1007/s10549-021-06147-1

PMID 33755864

发布时间 2021-06-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交